DXCM slides over 5% as price breaks below moving averages despite strong revenue gains

Traders Union
All News
Financial News
DexCom slides 5.3% today on weak action

Highlights

DexCom's fiscal 2025 revenue increased 22% to approximately $4.0 billion, driven by robust adoption of the G7 platform.
Operating income and margins improved, with fourth-quarter sales up 23% year-on-year, underscoring sustained business momentum.
DexCom trades below near-term moving averages amid selling pressure and volatility, but the longer-term trend remains bullish with a projected five-day range of $67.78 to $73.81.

Strong G7 platform growth persists despite persistent selling pressure

DexCom reported strong financial results for fiscal year 2025, with annual revenue of approximately $4.0 billion increasing by 22% from the prior year and higher operating income and margins. The G7 continuous glucose monitoring platform contributed to multiple quarters of double-digit growth, and fourth-quarter 2025 revenue reached about $1.1 billion, up 23% year-on-year. These results highlight ongoing business momentum, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, highlights that DexCom’s sharp 5.3% decline signals sellers overwhelming recent positive news. He points out that although fundamentals look strong, with double-digit revenue growth from the G7 platform, the price now sits below key moving averages and short-term technical levels act as a ceiling. He warns of mixed momentum and elevated volatility, indicating uncertainty and lack of strong conviction from buyers. Downside risks persist if $67.78 breaks, while longer-term support is not far below current levels. "Despite robust financials, the technical setup points to caution — I would wait for a clear base or decisive move above resistance before considering long positions."

Viktoras Karapetjanc, expert at Traders Union, notes DexCom’s strong revenue and margin gains reinforce a bullish institutional outlook. He sees the G7 rollout as fueling further double-digit growth and believes the market’s dip is a temporary reaction amid overall positive business momentum. For him, the technical structure remains constructive above the 200-day average, and upside leadership is favored if $71.06 is reclaimed. "With growth drivers intact and momentum mixed but skewed positive, I see further upside potential here and would look for new setups on rebounds above near-term resistance."

Jainam Mehta, market strategist, observes DexCom’s conflicting signals, with short-term technical pressure but underlying strength above its 200-day average. He suggests that recent volatility and persistent intraday lows could attract tactical contrarian trades if support near $67.78 holds. He notes that momentum divergences may offer nimble entry chances on a breakout above $71.06. "If buyers can reclaim $71.06 with volume, I’d consider a tactical long as the risk-reward setup may favor upside in the coming days."

Mixed momentum and volatile trade as short-term signals diverge

DexCom is now trading below its 20-day and 50-day moving averages, with the current price of $70.79 under both the $72.56 (MA-20) and $71.06 (MA-50) levels, indicating near-term selling pressure and hesitation from buyers. The price remains above the longer-term 200-day moving average at $67.43, reflecting that the broader trend still suggests underlying support, with the MA-50 vs MA-200 alignment signaling a bullish longer-term tone; the nearest resistance stands at $71.06, while support is expected near $67.78. Momentum signals are mixed. The Moving Average Convergence Divergence (MACD) points toward building bullish momentum, but the Average Directional Index (ADX) at 15.9 indicates limited trend strength. The Relative Strength Index (RSI) at 54.2 and Commodity Channel Index (CCI) at 69.17 each suggest a mild buy setup, but the Stochastic RSI sits at a neutral 47.69. Bull/Bear Power (BBP) at 1.94 means buyers are dominating near-term action, yet its overbought signal reinforces caution. The Awesome Oscillator (AO) also reads “Buy,” supporting the prevailing short-term up momentum. Intraday, DexCom is down to $70.79 after opening with an upside gap of $0.50 (0.67%), then falling $3.97 or 5.3% for the day and now trades near session lows. Intraday volatility stands at 5.50%, highlighting significant swings and persistent pressure after the open. Divergent momentum cues show a market searching for new direction, as bullish signals in some indicators counter intraday weakness and profit-taking.

Earlier, analysts noted that management transitions and strategic reviews can significantly impact investor sentiment and share performance for companies facing major structural changes. The latest technical signals and volatility in DexCom reinforce the importance of monitoring support at $67.78, as a sustained move below this level could intensify downside risk despite underlying long-term growth momentum.

Source of Data: DXCM Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.